Vantaggi dell'abbonamento

Sintesi dell'editore

Pharmaceutical companies that spend billions of dollars to develop new drugs do not want competitors to profit from inexpensive generic copies of blockbuster medicines. To avoid rivals, they fight for patent extensions, seek new uses for old products and, sometimes, prevent generic drug companies from obtaining samples.

"FDA Names and Shames Drugmakers to Encourage Generic Competition" is from the May 17, 2018 Business section of The New York Times. It was written by Sheila Kaplan and narrated by Keith Sellon-Wright.

©2017 The New York Times News Service Division of The New York Times Company (P)2017 Audible, Inc.

Cosa pensano gli ascoltatori di FDA Names and Shames Drugmakers to Encourage Generic Competition

Valutazione media degli utenti

Non ci sono recensioni disponibili